Skip to main content
Premium Trial:

Request an Annual Quote

Co-Diagnostics Posts Q1 Revenue Boost on SARS-CoV-2 Test Sales

NEW YORK — Co-Diagnostics on Thursday after the close of the market reported a massive jump in first quarter revenues, largely due to sales of its Logix Smart COVID-19 test for SARS-CoV-2.

For the three-month period ended March 31, Co-Diagnostics' revenues were $20.0 million, a more than 13-fold increase versus $1.5 million in the same period a year earlier.

Sales of the PCR-based Logix Smart test, which was CE-IVD marked in February 2020 and received Emergency Use Authorization from the US Food and Drug Administration shortly thereafter, accounted for most of those revenues.

Co-Diagnostics posted a first quarter net profit of $7.9 million, or $.26 per share, compared with a year-ago net loss of $1.1 million, or $.05 per share.

R&D spending in the quarter increased fivefold to $2.2 million from $400,022 the year before, reflecting the costs of developing a rapid point-of-care device for SARS-CoV-2 and other infectious diseases, as well as the impact of additional hires made to support the company's new product development activities.

SG&A expenses were up 141 percent to $4.1 million from $1.7 million, mostly due to increased compensation expenses.

At the end of March, Salt Lake City-based Co-Diagnostics had cash and cash equivalents of $57.8 million and marketable securities of $2.3 million.

Looking ahead, Co-Diagnostics said it expects second quarter revenues in the range of $20.0 million to $22.0 million, with earnings between $.19 and $.23 per share. Wall Street analysts, on average, are expecting $16.3 million in Q2 revenues.

In Friday morning trading on the Nasdaq, shares of Co-Diagnostics were up almost 11 percent at $7.93.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.